-
-
News from EIPG
- The risk of a biosimilar void in Europe
- The drug shortage situation – EIPG’s point of view
- EP’s draft position on Unitary SPC and SPC Regulation revision
- Reactions to the proposed ban of PFAS
- EC Communication (part 2): a Critical Medicines Alliance to support European pharma supply chain
- EC Communication (part 1): How to address critical medicines shortages
- The UK’s statutory scheme revision for branded medicines
